(HealthDay News) -- New research finds that the targeted cancer drug Tarceva nearly triples the amount of time lung cancer patients survive without a recurrence and has fewer side effects than standard chemotherapy.
The authors of a study appearing in the July 21 online issue of The Lancet Oncology recommend using Tarceva (erlotinib) as a first-line treatment for patients with advanced non-small-cell lung cancer who have the particular gene mutation this drug targets.
Other experts agreed.
"This is a very important study [because] it shows that we can identify patients with a specific genetic marker and direct specific treatment toward them," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La. Read more...
Immunice for Immune Support
Subscribe to:
Post Comments (Atom)
Dr. Group's Secret to Health Kit$39.94  Dr. Group's Secret to Health Kit offers simple at-home solutions for cleansing internally and externally thereby reducing toxins, restoring the body's natural healing process, and helping you achieve true health and happiness. |
Advanced Body Cleansing Kit$147.75 Advanced Body Cleansing Kit with Livatrex™, Oxy-Powder®, Latero-Flora™ and two bottles of ParaTrex®. |
No comments:
Post a Comment